Business
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financ
About this update from Vtv Therapeutics Inc.
[{"type":"image","alt":"vTv Therapeutics Inc.","displaySize":"","headline":null,"caption":"vTv Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AM4EHLX89ULuROtlqZ7i2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/AM4EHLX89ULuROtlqZ7i2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156}},"lazy":false},{"type":"text","content":"Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026","length":77,"tagName":"p"},{"type":"text","content":"Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout","length":95,"tagName":"p"},{"type":"text","content":"HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026. vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point with cash currently on hand.","length":772,"tagName":"p"},{"type":"text","content":"“We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized t...